1986
DOI: 10.1016/0277-5379(86)90003-9
|View full text |Cite
|
Sign up to set email alerts
|

Augmented natural killer activity in ovarian cancer patients treated with cimetidine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
9
0

Year Published

1988
1988
1999
1999

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 25 publications
(12 citation statements)
references
References 16 publications
1
9
0
Order By: Relevance
“…[15][16][17][18][19][20][21] Our current data confirm that PBMCs from patients with advanced ovarian carcinoma show a marked decrease in natural killer cytotoxicity compared with PMBCs from normal subjects, despite having normal proportions of natural killer cells, CD4ϩ T cells, and CD8ϩ T cells. Furthermore, no increases in other lymphocyte populations that exhibit suppressor activity were observed.…”
Section: Discussionsupporting
confidence: 66%
“…[15][16][17][18][19][20][21] Our current data confirm that PBMCs from patients with advanced ovarian carcinoma show a marked decrease in natural killer cytotoxicity compared with PMBCs from normal subjects, despite having normal proportions of natural killer cells, CD4ϩ T cells, and CD8ϩ T cells. Furthermore, no increases in other lymphocyte populations that exhibit suppressor activity were observed.…”
Section: Discussionsupporting
confidence: 66%
“…They have been shown to reduce primary tumor growth [34] and lung metastases [34,35] and inTumor immunotherapy with 1-1-2 receptor antagonists, indomethacin and IL-2 crease survival in tumor-bearing animals [34]. In human cancer patients, H-2RA have been reported to increase IL-2 production [48] and peripheral blood NK activity [31,32] and cause partial/ complete objective responses [36,37]. In several reports, human cancer patients given H-2RA therapy did not respond [49,50].…”
Section: Discussionmentioning
confidence: 99%
“…H-2RA have been shown to stimulate IgM and IgG immunoglobulin and IL-2 production [27], increase the response of lymphocytes to mitogens [28,29], enhance lymphocyte responsiveness in an allogeneic and autologous mixed lymphocyte reaction [30] and restore NK activity in ovarian cancer [31] and chronic lymphocytic leukemia [32] patients. H-2RA have also been reported to block the production of histamine-induced suppressor factor (HSF) by H-2R + T suppressor cells, thereby augmenting Band T-cell function [33].…”
Section: Introductionmentioning
confidence: 99%
“…A meta-analysis of a number of studies has also failed to demonstrate survival benefits with conventional cytotoxic agents (Hermans et al, 1993). The H 2 -receptor antagonist cimetidine is well tolerated, anecdotally linked to healing of malignant gastric ulcers and has been shown to inhibit suppressor T-lymphocyte function (Griswold et al, 1984;Kikuchi et al, 1986), leading to suggestions that it could have a useful role as an anticancer agent. We have failed to replicate the findings of Tonneson et al (1988), who reported median survival to be improved from 316 days in placebo recipients to 450 days in those given cimetidine 400 mg twice daily, with a corresponding improvement in relative survival rates from 28% to 45% at 1 year.…”
Section: mentioning
confidence: 99%
“…The postulated mechanisms of action are mediated by H 2 -receptor blockade of suppressor T-lymphocytes, leading to their functional inhibition and stimulation of natural killer cell activity (Griswold et al, 1984;Kikuchi et al, 1986) and antagonism of histamine-stimulated growth (Watson et al, 1993). Tonnesen et al (1988) conducted a randomized trial and reported that cimetidine appeared to improve survival in gastric cancer patients.…”
mentioning
confidence: 99%